Table 1. Demographic Characteristics of the Participants and Reasons for PCR Testing among Samples Used to Estimate BNT162b2 Vaccine Effectiveness.*.
| Characteristics | 0–13 Days after First Dose | ≥14 Days after First Dose and No Second Dose | First Month after Second Dose | |||
|---|---|---|---|---|---|---|
| Case Participants: PCR-Positive (N=115,326) |
Controls: PCR-Negative (N=115,326) |
Case Participants: PCR-Positive (N=113,830) |
Controls: PCR-Negative (N=113,830) |
Case Participants: PCR-Positive (N=115,913) |
Controls: PCR-Negative (N=115,913) |
|
| Median age (IQR) — yr | 31 (21–39) | 31 (21–39) | 31 (21–39) | 31 (21–39) | 31 (21–39) | 31 (22–39) |
| Age group — no. (%) | ||||||
| <20 yr | 26,915 (23.3) | 26,915 (23.3) | 26,813 (23.6) | 26,813 (23.6) | 26,822 (23.1) | 26,822 (23.1) |
| 20–29 yr | 24,879 (21.6) | 24,879 (21.6) | 24,567 (21.6) | 24,567 (21.6) | 24,770 (21.4) | 24,770 (21.4) |
| 30–39 yr | 36,749 (31.9) | 36,749 (31.9) | 36,150 (31.8) | 36,150 (31.8) | 36,896 (31.8) | 36,896 (31.8) |
| 40–49 yr | 19,154 (16.6) | 19,154 (16.6) | 18,820 (16.5) | 18,820 (16.5) | 19,382 (16.7) | 19,382 (16.7) |
| 50–59 yr | 6,083 (5.3) | 6,083 (5.3) | 5,959 (5.2) | 5,959 (5.2) | 6,350 (5.5) | 6,350 (5.5) |
| 60–69 yr | 1,229 (1.1) | 1,229 (1.1) | 1,195 (1.0) | 1,195 (1.0) | 1,326 (1.1) | 1,326 (1.1) |
| ≥70 yr | 317 (0.3) | 317 (0.3) | 326 (0.3) | 326 (0.3) | 367 (0.3) | 367 (0.3) |
| Sex | ||||||
| Male | 79,255 (68.7) | 79,255 (68.7) | 78,148 (68.7) | 78,148 (68.7) | 79,750 (68.8) | 79,750 (68.8) |
| Female | 36,071 (31.3) | 36,071 (31.3) | 35,682 (31.3) | 35,682 (31.3) | 36,163 (31.2) | 36,163 (31.2) |
| Nationality† | ||||||
| Bangladeshi | 8,323 (7.2) | 8,323 (7.2) | 8,229 (7.2) | 8,229 (7.2) | 8,326 (7.2) | 8,326 (7.2) |
| Egyptian | 6,734 (5.8) | 6,734 (5.8) | 6,629 (5.8) | 6,629 (5.8) | 6,859 (5.9) | 6,859 (5.9) |
| Filipino | 10,713 (9.3) | 10,713 (9.3) | 10,535 (9.3) | 10,535 (9.3) | 10,674 (9.2) | 10,674 (9.2) |
| Indian | 29,914 (25.9) | 29,914 (25.9) | 29,536 (25.9) | 29,536 (25.9) | 30,325 (26.2) | 30,325 (26.2) |
| Nepalese | 10,505 (9.1) | 10,505 (9.1) | 10,367 (9.1) | 10,367 (9.1) | 10,496 (9.1) | 10,496 (9.1) |
| Pakistani | 5,793 (5.0) | 5,793 (5.0) | 5,735 (5.0) | 5,735 (5.0) | 5,837 (5.0) | 5,837 (5.0) |
| Qatari | 17,375 (15.1) | 17,375 (15.1) | 17,087 (15.0) | 17,087 (15.0) | 17,147 (14.8) | 17,147 (14.8) |
| Sri Lankan | 3,756 (3.3) | 3,756 (3.3) | 3,732 (3.3) | 3,732 (3.3) | 3,784 (3.3) | 3,784 (3.3) |
| Sudanese | 3,249 (2.8) | 3,249 (2.8) | 3,242 (2.8) | 3,242 (2.8) | 3,285 (2.8) | 3,285 (2.8) |
| Other nationalities‡ | 18,964 (16.4) | 18,964 (16.4) | 18,738 (16.5) | 18,738 (16.5) | 19,180 (16.5) | 19,180 (16.5) |
| Reason for PCR testing | ||||||
| Clinical suspicion | 40,768 (35.4) | 40,768 (35.4) | 40,261 (35.4) | 40,261 (35.4) | 41,138 (35.5) | 41,138 (35.5) |
| Contact tracing | 18,772 (16.3) | 18,772 (16.3) | 18,481 (16.2) | 18,481 (16.2) | 18,666 (16.1) | 18,666 (16.1) |
| Routine health care testing | 14,479 (12.6) | 14,479 (12.6) | 14,351 (12.6) | 14,351 (12.6) | 14,536 (12.5) | 14,536 (12.5) |
| Survey | 27,972 (24.3) | 27,972 (24.3) | 27,484 (24.1) | 27,484 (24.1) | 27,883 (24.1) | 27,883 (24.1) |
| Individual request | 12,914 (11.2) | 12,914 (11.2) | 12,838 (11.3) | 12,838 (11.3) | 13,233 (11.4) | 13,233 (11.4) |
| Other | 421 (0.4) | 421 (0.4) | 415 (0.4) | 415 (0.4) | 457 (0.4) | 457 (0.4) |
*
Data for other time-since-vaccination analyses are shown in Tables S2 and S3 in the Supplementary Appendix. Case participants and controls were matched one to one according to sex, 10-year age group, nationality, reason for polymerase-chain-reaction (PCR) testing, and calendar week of PCR test. Percentages may not total 100 because of rounding. IQR denotes interquartile range.
†
Nationalities were chosen to represent the most populous groups in Qatar.
‡
The category of other nationalities includes 108 other nationalities in Qatar for 0 to 13 days after the first dose, 106 other nationalities for 14 or more days after the first dose and no second dose, and 108 other nationalities for the first month after the second dose.